Is Amgen Stock a Buy?
(NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant and Dow Jones Industrial Average component, pending clinical-trial data from its drug pipeline has added a layer of uncertainty.
On the other hand, the company continues to deliver strong growth with overall positive fundamentals. So is now a good time to pick up some Amgen shares? Here's what you need to know.
Amgen is recognized as a biotech pioneer with a long history of groundbreaking discoveries. From developing Epogen in the 1980s as one of the first recombinant DNA technology-based treatments for anemia to launching the first-of-its-kind monoclonal-antibody therapy against cancer with Neulasta in 2003, that tradition of innovation has continued.
Source Fool.com
Amgen Inc. Aktie
Starke Kaufneigung bei Amgen Inc., mit mehr Buy- als Sell-Einschätzungen.
Für Amgen Inc. ergibt sich ein Potenzial von -5.46%, obwohl das Kursziel von 336 € den aktuellen Kurs von 355.4 € unterschreitet.
